Receptor (biochemistry) - Pharmacology and Regulation of Receptors

Functional Classes of Ligands and Drug-Receptor Interactions Introduction When a drug binds to a receptor, two fundamental properties determine what happens: affinity and efficacy. Understanding the distinction between these concepts is essential for classifying ligands and predicting how they will affect the body. Affinity is the ability of a drug to bind to a receptor—it describes the strength and likelihood of the drug-receptor interaction. Efficacy is the ability of the bound drug-receptor complex to produce a biological response. These are independent properties: a drug can bind strongly but produce no effect, or bind weakly but trigger a powerful response. This distinction reveals why simple "receptor occupancy" doesn't fully explain drug effects. The original Occupation Theory proposed that drug response is proportional to the fraction of receptors occupied, but this model is incomplete. The functional classification of ligands below represents our modern understanding based on both binding and activation. Full Agonists A full agonist is a ligand that binds to a receptor and produces the maximum possible response—what we call 100% efficacy. When a full agonist occupies receptors, it drives the system toward its maximum output. The classic example is a key fitting perfectly into a lock and turning it completely. Epinephrine acting on beta-adrenergic receptors is a natural full agonist for most tissues it acts upon. Full agonists are the baseline for measuring other ligands' effects. If a full agonist produces a maximum contraction of heart muscle, we compare all other ligands to that standard response. Partial Agonists A partial agonist binds to a receptor but produces only a submaximal response—efficacy between 0% and 100%—even when it occupies all available receptors. This is conceptually tricky: even with 100% receptor occupancy, a partial agonist cannot produce as much effect as a full agonist. This happens because the partial agonist-receptor complex is inherently less efficient at triggering the downstream signaling cascade. A useful analogy: imagine a switch that can be turned to varying degrees. A full agonist turns it fully "on," while a partial agonist only partially turns it on, no matter how many switches you activate. An important clinical consequence emerges when a partial agonist is present alongside a full agonist. The partial agonist competes for receptor binding and actually reduces the maximum response compared to full agonist alone. This makes partial agonists useful for situations where you want a "ceiling effect"—limiting the maximum possible response to avoid overactivation. <extrainfo> Buprenorphine is a classic example: it's a partial agonist at opioid receptors, which is why it's safer in overdose than full opioid agonists—it cannot produce the same maximal respiratory depression. </extrainfo> Antagonists Antagonists bind to receptors without activating them (0% efficacy) and physically block agonists from binding. They reduce the response caused by agonists. There are two mechanistically distinct types: Competitive Antagonists Competitive (reversible) antagonists bind to the same site as agonists and compete directly for receptor occupancy. The key word is "reversible"—the antagonist can dissociate from the receptor, and if agonist concentration increases, agonist can outcompete the antagonist for binding. In a dose-response curve, competitive antagonism is recognized by a rightward shift of the agonist curve—you need more agonist to achieve the same effect because some receptors are blocked by antagonist. However, the maximum response remains unchanged because sufficiently high agonist concentrations will still occupy enough receptors. Irreversible Antagonists Irreversible antagonists form very strong bonds (usually covalent) with receptors, making dissociation extremely slow or impossible. New receptor synthesis is required to reverse the effect. <extrainfo> Omeprazole, used to reduce stomach acid, is an irreversible antagonist of the proton pump. Its long duration of action reflects the time needed for the body to make new pump proteins. </extrainfo> On a dose-response curve, irreversible antagonism causes a rightward shift AND a reduction in maximum response—you lose receptors permanently (until new ones are made), so no amount of agonist can fully overcome the antagonism. Inverse Agonists This class requires understanding constitutive activity: many receptors display baseline activity even without any ligand binding. They're "active by default." An inverse agonist binds to a receptor and reduces its constitutive activity below the basal level, producing negative efficacy. Unlike antagonists (which are neutral, producing 0% efficacy), inverse agonists actively suppress the receptor. The figure above illustrates the efficacy spectrum: full agonists are at 100%, antagonists at 0%, and inverse agonists in the negative range. This distinction matters clinically. For example, beta-blockers used to treat hypertension have some inverse agonist activity—they not only block epinephrine but also reduce the heart's baseline sympathetic tone below normal. Allosteric Modulators Allosteric modulators bind to a different site on the receptor than where agonists bind (the "orthosteric" site). By binding to this alternate location, they modify how effectively the agonist can activate the receptor. An allosteric enhancer (positive modulator) increases the agonist's effect—it makes the agonist more effective without itself producing activation. An allosteric inhibitor (negative modulator) decreases the agonist's effect. This mechanism allows cells to fine-tune responses without blocking the agonist entirely. Allosteric modulation is attractive clinically because it's selectivity-preserving: since allosteric sites are often more variable between receptor subtypes than orthosteric sites, allosteric drugs can target specific receptor variants while sparing others. The Spare Receptor Concept Here's something counterintuitive: in many biological systems, maximal response can be achieved without occupying all available receptors. This phenomenon is explained by the spare receptor (or receptor reserve) concept. Some tissues maintain more receptors than necessary to produce their maximum response. Once enough receptors are activated to trigger full effect, additional receptors are "spare." This provides biological advantage: the tissue can respond maximally to low agonist concentrations without requiring saturation. The spare receptor concept also explains why partial agonists can sometimes produce near-maximal responses in tissues with large receptor reserves. With many spare receptors, even a partial agonist producing submaximal response per receptor might activate enough total receptors to achieve the tissue's maximum output. <extrainfo> This concept is crucial for understanding why some tissues show different sensitivities to the same drug. A tissue with few spare receptors requires high agonist occupancy to respond, while a tissue with many spare receptors responds at lower occupancy. </extrainfo> Receptor Regulation: Up- and Down-Regulation Cells don't passively accept constant agonist signaling. Instead, they actively adjust receptor numbers to maintain appropriate sensitivity. Down-regulation occurs when cells reduce the number of receptors in response to chronic agonist exposure. The cell becomes less sensitive to that agonist. Up-regulation is the opposite—cells increase receptor number when chronically deprived of agonist, becoming more sensitive. This explains why tolerance develops to some drugs: continued exposure causes down-regulation. Conversely, stopping a drug can produce rebound supersensitivity as up-regulated receptors suddenly have agonist removed. Desensitization Mechanisms Beyond changing receptor numbers, cells employ rapid mechanisms to reduce receptor responsiveness, collectively called desensitization: Uncoupling In G protein-coupled receptors (GPCRs), activated receptors normally recruit G proteins to trigger downstream signaling. During uncoupling, the receptor becomes phosphorylated (often by kinases like GRK—G protein-coupled receptor kinase) and β-arrestin proteins bind to it. These bound proteins physically block G protein recruitment, silencing the signal even though the agonist remains bound. This happens within seconds to minutes and is reversible—if the agonist dissociates, dephosphorylation can restore G protein coupling. Sequestration Many hormone receptors and GPCRs are internalized via receptor sequestration: the cell retracts the receptor from the cell surface into intracellular compartments. This physically removes receptors from where agonist can reach them, reducing responsiveness without necessarily degrading the receptor. <extrainfo> Sequestration differs from down-regulation: sequestered receptors may be recycled back to the surface once the agonist is removed, whereas down-regulation (degradation) requires new receptor synthesis. </extrainfo>